Patrick Gallagher - Protea Biosciences Director
Director
Mr. Patrick Gallagher, CFA., is an Independent Director of the Company. Mr. Gallagher is a CFA and an accomplished Capital Markets executive, advisor and investor with a distinguished record of success in both the public and private markets with a focus on healthcare, agriculture and industrials. He has over two decades of experience on Wall Street and extensive experience in alternative investments, research and marketing. He is a Managing Director and Head of Institutional Sales for Laidlaw Company Ltd., a healthcare focused investment bank. Mr. Gallagher cofounded Black Diamond Research, LLC, an independent sellside research firm specializing in healthcare and industrial investing, financing and operations, serving the institutional investing community at large. As CEO of BDR, Mr. Gallagher oversaw institutional research and sales. Prior, he held various sales positions at Kidder Peabody, PaineWebber, New Vernon Associates and Concept Capital. Mr. Gallagher served as VP of Business Development and Investor Relations as well as a strategic consultant for Kinex Pharmaceuticals, a biotechnology firm focused on nextgeneration therapies in oncology and immunology. He also serves as an advisor to CHD Biosciences, a novel antimicrobial company. Mr. Gallagher sits on the board of directors for BioSig Technologies, Inc., a medical technology company that is developing a proprietary platform in the electrophysiology space since 2015.
| Age | 51 |
| Tenure | 9 years |
| Professional Marks | CFA |
| Phone | 304-292-2226 |
| Web | http://www.proteabio.com |
Patrick Gallagher Latest Insider Activity
Tracking and analyzing the buying and selling activities of Patrick Gallagher against Protea Biosciences otc bb equity is an integral part of due diligence when investing in Protea Biosciences. Patrick Gallagher insider activity provides valuable insight into whether Protea Biosciences is net buyers or sellers over its current business cycle. Note, Protea Biosciences insiders must abide by specific rules, including filing SEC forms every time they buy or sell Protea Biosciences'shares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Patrick Gallagher few days ago Acquisition by Patrick Gallagher of 1233 shares of Arthur J subject to Rule 16b-3 |
Protea Biosciences Management Efficiency
The company has return on total asset (ROA) of (104.33) % which means that it has lost $104.33 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (31.9) %, meaning that it created substantial loss on money invested by shareholders. Protea Biosciences' management efficiency ratios could be used to measure how well Protea Biosciences manages its routine affairs as well as how well it operates its assets and liabilities.The company currently holds 10.93 M in liabilities. Protea Biosciences has a current ratio of 0.04, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist Protea Biosciences until it has trouble settling it off, either with new capital or with free cash flow. So, Protea Biosciences' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Protea Biosciences sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Protea to invest in growth at high rates of return. When we think about Protea Biosciences' use of debt, we should always consider it together with cash and equity.
Similar Executives
| Showing other executives | DIRECTOR Age | ||
| Alberto Gonzalez | Fomento Economico Mexicano | 88 | |
| Paul Leand | SFL Corporation | 50 | |
| Stefan Descheemaeker | Anheuser Busch Inbev | 58 | |
| Olivier Goudet | Anheuser Busch Inbev | 54 | |
| Ricardo Escajadillo | Fomento Economico Mexicano | 67 | |
| Mark Winkelman | Anheuser Busch Inbev | 69 | |
| Gary Vogel | SFL Corporation | 55 | |
| William Gifford | Anheuser Busch Inbev | 51 | |
| Mariusz Jamka | Anheuser Busch Inbev | N/A | |
| Kate Blankenship | SFL Corporation | 52 | |
| Georgina Sousa | SFL Corporation | 66 | |
| Keesjan Cordia | SFL Corporation | 46 | |
| Gregory Fisher | Encore Wire | 67 | |
| Carlos Ancira | Fomento Economico Mexicano | 63 | |
| Eva Gonda | Fomento Economico Mexicano | 56 | |
| Robert Denham | Fomento Economico Mexicano | 75 | |
| Alberto Bailleres | Fomento Economico Mexicano | 83 | |
| Elio Sceti | Anheuser Busch Inbev | 55 | |
| Paul Ruart | Anheuser Busch Inbev | 53 | |
| Maria Aramburuzabala | Anheuser Busch Inbev | 57 | |
| Donald Courtney | Encore Wire | 87 | |
Management Performance
| Return On Equity | -31.9 | |||
| Return On Asset | -104.33 |
Protea Biosciences Leadership Team
Elected by the shareholders, the Protea Biosciences' board of directors comprises two types of representatives: Protea Biosciences inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Protea. The board's role is to monitor Protea Biosciences' management team and ensure that shareholders' interests are well served. Protea Biosciences' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Protea Biosciences' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Leonard Harris, Independent Director | ||
| Stephen Turner, Chairman, CEO and Pres | ||
| Gregory Kilby, COO and VP of Operations | ||
| Edwin Roberson, Independent Director | ||
| Stanley Hostler, VP, Secretary, Director and Member of Audit Committee | ||
| Steven Antoline, Independent Director | ||
| Edward Hughes, CFO | ||
| Scott Segal, Independent Director | ||
| Ed Roberson, Independent Director | ||
| Patrick Gallagher, Director | ||
| Andrew Zulauf, Independent Director | ||
| Josiah Austin, Independent Director | ||
| Matthew Powell, Chief Science Officer and VP of RandD | ||
| David Halverson, Vice President Chief Business Officer | ||
| Maged Shenouda, Director |
Protea Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right otc bb equity is not an easy task. Is Protea Biosciences a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -31.9 | |||
| Return On Asset | -104.33 | |||
| Operating Margin | (261.55) % | |||
| Current Valuation | 11.29 M | |||
| Shares Outstanding | 8.03 M | |||
| Shares Owned By Insiders | 49.85 % | |||
| Shares Owned By Institutions | 0.07 % | |||
| Price To Earning | (0.23) X | |||
| Price To Sales | 0.14 X | |||
| Revenue | 2.07 M |
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Protea Biosciences in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Protea Biosciences' short interest history, or implied volatility extrapolated from Protea Biosciences options trading.
Becoming a Better Investor with Macroaxis
Macroaxis puts the power of mathematics on your side. We analyze your portfolios and positions such as Protea Biosciences using complex mathematical models and algorithms, but make them easy to understand. There is no real person involved in your portfolio analysis. We perform a number of calculations to compute absolute and relative portfolio volatility, correlation between your assets, value at risk, expected return as well as over 100 different fundamental and technical indicators.Build Optimal Portfolios
Align your risk with return expectations
Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in price. Note that the Protea Biosciences information on this page should be used as a complementary analysis to other Protea Biosciences' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Equity Analysis module to research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities.
Other Consideration for investing in Protea OTC BB Equity
If you are still planning to invest in Protea Biosciences check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Protea Biosciences' history and understand the potential risks before investing.
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| Stocks Directory Find actively traded stocks across global markets | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges |